Neuroinflammation is an early detectable marker of mild cognitive impairment, the transition state between normal cognition and dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Research
28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Resistance exercise is used extensively in athletic and general populations to induce neuromuscular adaptations to increase muscle size and performance. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Since environmental, socioeconomic, and individual risk factors contribute to dementia, we proposed a Comprehensive, Customized, Cost-effective APProach (the CCC-APP) implemented in actionable units with the focus on promoting brain health (eumentia). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The socio-economic and health consequences of our ageing population are well documented, with older adults living in long-term care facilities amongst the frailest possessing specific and significant healthcare and social care needs. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Early-onset dementia (EOD) defines all dementia related conditions with an onset before the age of 65 years. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Poor sleep efficiency and sleep fragmentation are linked with poorer executive function and increased risk of dementia during follow-up. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Disruptions of circadian rhythms and sleep cycles are common among neurodegenerative diseases and can occur at multiple levels. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Sedative antidepressants are commonly used drugs in the treatment of insomnia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
41/100
Aging is associated with changes in sleep structure and cerebral deposition of amyloid beta and tau proteins. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
41/100
We have entered an era of a steep increase in the absolute and relative number of older people. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Patients suffering from neurodegenerative conditions frequently report sleep complaints, such as insomnia and excessive daytime sleepiness. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Insomnia is defined as difficulties of initiating and maintaining sleep, early awakening and poor subjective sleep quality despite adequate opportunity and circumstances for sleep with impairment of daytime performance. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Older adults who do not sleep well frequently have difficulty sustaining attention, display slower physical response times, and have memory issues that may contribute to depression or early dementia. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Women have increased risks for both sleep disturbances and disorders and for mental health issues throughout their lives, starting in adolescence. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The hypocretins (Hcrts), also known as orexins, are two neuropeptides produced exclusively in the lateral hypothalamus. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
A growing number of studies in animal models have highlighted the link between sleep disorders and Alzheimer's disease (AD). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Our aim was to determine whether the genetic liability to sleep and pain-related traits have a causal effect on risk of neurodegeneration in individuals of predominantly European ancestry. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Sleep plays a critical role in homeostasis of the body and mind. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Sleep plays an important role in homeostasis, brain plasticity, clearance of neurotoxins, cognition, memory, concentration, performance, and the regulation of the temperature, endocrine and immunological systems. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is considered to be the most typical form of dementia that provokes irreversible cognitive impairment. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
41/100
Although poor sleep quality and extreme sleep durations have been associated with brain atrophy and dementia, it is unclear whether sleep disturbances contribute to neural injury in the absence of neurodegeneration and cognitive impairment. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
A growing number of studies, in animal models and humans, have highlighted the link between sleep and Alzheimer's disease (AD) pathophysiology. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This review explores the interface between circadian timekeeping and the regulation of brain function by astrocytes. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Short sleep duration has been linked to the development of neurocognitive disorders. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This cycle is challenging to study, as its bidirectional nature renders cause difficult to disentangle from effect. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →